Jeanne Chiaravalli

Paris, 75015, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Design, synthesis, biophysical and biological evaluation of original condensed pyrrolopyrimidine and pyrrolopyridine ligands as anti-SARS-CoV-2 agents targeting G4.

Design, synthesis, biophysical and biological evaluation of original condensed pyrrolopyrimidine and pyrrolopyridine ligands as anti-SARS-CoV-2 agents targeting G4.

Journal: European journal of medicinal chemistry

Published: February 21, 2025

High Content Screening Assay of Inhibitors of the Legionella Pneumophila Histone Methyltransferase RomA in Infected Cells.

High Content Screening Assay of Inhibitors of the Legionella Pneumophila Histone Methyltransferase RomA in Infected Cells.

Journal: Chembiochem : a European journal of chemical biology

Published: March 31, 2024

High-throughput screening identifies broad-spectrum Coronavirus entry inhibitors.

High-throughput screening identifies broad-spectrum Coronavirus entry inhibitors.

Journal: iScience

Published: December 26, 2023

Targeting ACE2 with a camelid antibody inhibits SARS-CoV-2 binding and has protective effects in vivo.

Targeting ACE2 with a camelid antibody inhibits SARS-CoV-2 binding and has protective effects in vivo.

Journal: Nature communications

Published: November 22, 2023

Effective Inhibition of TDP-43 Aggregation by Native State Stabilization.

Effective Inhibition of TDP-43 Aggregation by Native State Stabilization.

Journal: Angewandte Chemie (International ed. in English)

Published: October 09, 2023

Enhanced neutralization escape to therapeutic monoclonal antibodies by SARS-CoV-2 omicron sub-lineages.

Enhanced neutralization escape to therapeutic monoclonal antibodies by SARS-CoV-2 omicron sub-lineages.

Journal: iScience

Published: December 22, 2022

Potent human broadly SARS-CoV-2-neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2.

Potent human broadly SARS-CoV-2-neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2.

Journal: The Journal of experimental medicine

Published: April 12, 2022

A highly sensitive cell-based luciferase assay for high-throughput automated screening of SARS-CoV-2 nsp5/3CLpro inhibitors.

A highly sensitive cell-based luciferase assay for high-throughput automated screening of SARS-CoV-2 nsp5/3CLpro inhibitors.

Journal: bioRxiv : the preprint server for biology

Published: January 04, 2022

A highly sensitive cell-based luciferase assay for high-throughput automated screening of SARS-CoV-2 nsp5/3CLpro inhibitors.

A highly sensitive cell-based luciferase assay for high-throughput automated screening of SARS-CoV-2 nsp5/3CLpro inhibitors.

Journal: Antiviral research

Published: October 13, 2021

SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution.

SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution.

Journal: Nature microbiology

Published: June 26, 2021

Characterising proteolysis during SARS-CoV-2 infection identifies viral cleavage sites and cellular targets with therapeutic potential.

Characterising proteolysis during SARS-CoV-2 infection identifies viral cleavage sites and cellular targets with therapeutic potential.

Journal: Nature communications

Published: February 04, 2021

Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug chlorpromazine.

Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug chlorpromazine.

Journal: International journal of antimicrobial agents

Published: June 15, 2020

Showing 1-12 of 17

Last Updated: 09/26/2026